Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: a systematic review from 2000 to 2020

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1478-6362

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: a systematic review from 2000 to 2020 ; volume:23 ; number:1 ; day:22 ; month:2 ; year:2021 ; pages:1-14 ; date:12.2021
Arthritis Research & Therapy ; 23, Heft 1 (22.2.2021), 1-14, 12.2021

Creator: Fernández-Martín, Silvia
López-Peña, Mónica
Muñoz, Fernando
Permuy, María
González-Cantalapiedra, Antonio

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13075-021-02446-6

URN: urn:nbn:de:101:1-2021041006220691638251

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:53 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Fernández-Martín, Silvia
López-Peña, Mónica
Muñoz, Fernando
Permuy, María
González-Cantalapiedra, Antonio
SpringerLink (Online service)

Other Objects (12)

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Current Disease-Modifying Therapies in Multiple Sclerosis

Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin

Disease-modifying effects of phosphocitrate and phosphocitrate-β-ethyl ester on partial meniscectomy-induced osteoarthritis

Disease-modifying treatments in Alzheimer’s disease

MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy

The disease-modifying effect of dehydroepiandrosterone in different stages of experimentally induced osteoarthritis: a histomorphometric study

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Lithium as a disease-modifying agent for prion diseases

Current experimental disease-modifying therapeutics for multiple system atrophy

Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Current Disease-Modifying Therapies in Multiple Sclerosis

Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin

Disease-modifying effects of phosphocitrate and phosphocitrate-β-ethyl ester on partial meniscectomy-induced osteoarthritis

Disease-modifying treatments in Alzheimer’s disease

MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy

The disease-modifying effect of dehydroepiandrosterone in different stages of experimentally induced osteoarthritis: a histomorphometric study

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Lithium as a disease-modifying agent for prion diseases

Current experimental disease-modifying therapeutics for multiple system atrophy

Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Current Disease-Modifying Therapies in Multiple Sclerosis

Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin

Disease-modifying effects of phosphocitrate and phosphocitrate-β-ethyl ester on partial meniscectomy-induced osteoarthritis

Disease-modifying treatments in Alzheimer’s disease

MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy

The disease-modifying effect of dehydroepiandrosterone in different stages of experimentally induced osteoarthritis: a histomorphometric study

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Lithium as a disease-modifying agent for prion diseases

Current experimental disease-modifying therapeutics for multiple system atrophy

Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: a systematic review from 2000 to 2020

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Current Disease-Modifying Therapies in Multiple Sclerosis

Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin

Disease-modifying effects of phosphocitrate and phosphocitrate-β-ethyl ester on partial meniscectomy-induced osteoarthritis

Disease-modifying treatments in Alzheimer’s disease

MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy

The disease-modifying effect of dehydroepiandrosterone in different stages of experimentally induced osteoarthritis: a histomorphometric study

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Lithium as a disease-modifying agent for prion diseases

Current experimental disease-modifying therapeutics for multiple system atrophy

Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Current Disease-Modifying Therapies in Multiple Sclerosis

Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin

Disease-modifying effects of phosphocitrate and phosphocitrate-β-ethyl ester on partial meniscectomy-induced osteoarthritis

Disease-modifying treatments in Alzheimer’s disease

MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy

The disease-modifying effect of dehydroepiandrosterone in different stages of experimentally induced osteoarthritis: a histomorphometric study

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Lithium as a disease-modifying agent for prion diseases

Current experimental disease-modifying therapeutics for multiple system atrophy

Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Current Disease-Modifying Therapies in Multiple Sclerosis

Development of a Disease-Modifying OA Drug (DMOAD) in Knee Osteoarthritis: The Example of Sprifermin

Disease-modifying effects of phosphocitrate and phosphocitrate-β-ethyl ester on partial meniscectomy-induced osteoarthritis

Disease-modifying treatments in Alzheimer’s disease

MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy

The disease-modifying effect of dehydroepiandrosterone in different stages of experimentally induced osteoarthritis: a histomorphometric study

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Lithium as a disease-modifying agent for prion diseases

Current experimental disease-modifying therapeutics for multiple system atrophy

Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis

Related objects

Reset password